Docetaxel (Taxotere®)
Sponsors
Hoffmann-La Roche, H. Lee Moffitt Cancer Center and Research Institute, Sanofi, National University Hospital, Singapore, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
Breast CancerCarcinomaHER2-Negative Advanced Breast CancerNon Small Cell LungNon-Small Cell Lung CancerOvarian CancerSolid Tumors
Phase 1
Phase 2
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
CompletedNCT00077857
Start: 2003-07-31End: 2010-03-31Updated: 2013-05-10
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
CompletedNCT00231465
Start: 2003-07-31End: 2012-08-31Updated: 2017-03-03
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
CompletedNCT00296816
Start: 2006-03-31End: 2011-08-31Updated: 2012-08-23
Phase 3
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
CompletedNCT00532155
Start: 2007-09-30End: 2011-10-31Updated: 2025-09-10
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
Not yet recruitingNCT07805135
Start: 2026-08-31End: 2029-06-01Target: 430Updated: 2026-09-04